Generics

Products & dossiers

We develop and manufacture our products after the careful selection and qualification of our partners. Product quality, supply chain stability and sustainability are of key importance to us.

A full list of our dossiers available for in-licensing or in development can be found below.

Dossier list

Search:

Molecule	Originator brand	Indication	Strengths	Administration	Main sector¹	Type of dossier	Dossier availability	EU Data protection²	Expected launch³

Molecule	Originator brand	Indication	Strengths	Administration	Main sector¹	Type of dossier	Dossier availability	EU Data protection²	Expected launch³
Caspofungin	Cancidas® by Merck	Antifungal, systemic	50 mg, 70 mg	Parenteral	Hospital	EU-CTD	Available	Expired	Commercial
Anidulafungin	Ecalta® by Pfizer	Antifungal, systemic	100 mg	Parenteral	Hospital	EU-CTD	Available	Expired	Commercial
Micafungin	Mycamine® by Astellas	Antifungal, systemic	50 mg, 100 mg	Parenteral	Hospital	EU-CTD	Available	Expired	Commercial
Ticagrelor	Brilique® by AstraZeneca	Anticoagulant	60 mg, 90 mg	Oral	Retail	EU-CTD	Available	Expired	06.2025
Tafamidis Meglumine	Vyndaqel® by Pfizer	Amyloidosis	20 mg	Oral	Mixed	EU-CTD	Available	Expired	11.2026
Tafamidis free acid	Vyndaqel® by Pfizer	Amyloidosis	61 mg	Oral	Mixed	EU-CTD	Pipeline	02.2030	TBD
Macitentan	Opsumit® by Actelion	Pulmonary hypertension	10 mg	Oral	Mixed	EU-CTD	Available	Expired	12.2026
Isavuconazole	Cresemba® by Basilea	Antimycotic	100 mg	Oral	Hospital	EU-CTD	Q2’2026	10.2027	2028³
Isavuconazole	Cresemba® by Basilea	Antimycotic	200 mg	Parenteral	Hospital	EU-CTD	Q2’2026	10.2027	2028³
Nusinersen	Spinraza® by Biogen	Spinal muscular atrophy	12 mg	Parenteral	Hospital	EU-CTD	Pipeline	06.2029	06.2031
Risdiplam	Evrisdy® by Roche	Spinal muscular atrophy	60 mg	Oral	Mixed	EU-CTD	Pipeline	03.2031	2036

Product List Version: March 2025

_________

¹Main sector is based on average IQVIA sales distribution by Standard Units in Europe

²Expected launch date applies for market entry of generic products in major European countries. Please check specific patent situation in any particular country of interest

³ Launch in the market dependent on registration timelines.

test123

Frank Buennig

VP Sales FDF & Nutrition

Interested in in-licensing?

If you are interested in in-licensing our dossiers, please contact us.

For information on our business model of the co-development of generics, click the button below.

Generics

Products & dossiers

Dossier list

test123

Frank Buennig

Interested in in-licensing?

Contact

Our business

Company